ATE150299T1 - Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker - Google Patents

Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker

Info

Publication number
ATE150299T1
ATE150299T1 AT90302365T AT90302365T ATE150299T1 AT E150299 T1 ATE150299 T1 AT E150299T1 AT 90302365 T AT90302365 T AT 90302365T AT 90302365 T AT90302365 T AT 90302365T AT E150299 T1 ATE150299 T1 AT E150299T1
Authority
AT
Austria
Prior art keywords
tetrahydro
inflammation
phenyl
treatment
derivatives
Prior art date
Application number
AT90302365T
Other languages
English (en)
Inventor
Kenneth B Koe
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23244506&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE150299(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE150299T1 publication Critical patent/ATE150299T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90302365T 1989-03-07 1990-03-06 Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker ATE150299T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/320,014 US4981870A (en) 1989-03-07 1989-03-07 Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Publications (1)

Publication Number Publication Date
ATE150299T1 true ATE150299T1 (de) 1997-04-15

Family

ID=23244506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90302365T ATE150299T1 (de) 1989-03-07 1990-03-06 Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker

Country Status (17)

Country Link
US (2) US4981870A (de)
EP (1) EP0386997B1 (de)
JP (2) JPH0714870B2 (de)
KR (1) KR920005810B1 (de)
AT (1) ATE150299T1 (de)
AU (1) AU610036B2 (de)
CA (1) CA2011428C (de)
DE (1) DE69030212T2 (de)
DK (1) DK0386997T3 (de)
HU (1) HU221624B1 (de)
IE (1) IE81047B1 (de)
IL (1) IL93576A (de)
MY (1) MY106272A (de)
NZ (1) NZ232800A (de)
PH (1) PH26542A (de)
PT (1) PT93351B (de)
ZA (1) ZA901743B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
AU658134B2 (en) * 1989-12-28 1995-04-06 Virginia Commonwealth University Sigma receptor ligands and the use thereof
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
EP0714292A4 (de) * 1993-06-23 1996-10-09 Cambridge Neuroscience Inc Sigma-rezeptor-liganden und ihre verwendung
ES2074946B1 (es) * 1993-07-19 1996-06-16 Ferrer Int Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida.
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
NZ513456A (en) 1997-07-01 2003-02-28 Pfizer Sertraline acetate, L-lactate and L-aspartate, processes for their preparation and their uses in psychotic disorders
EP1239839A2 (de) 1999-12-23 2002-09-18 Pfizer Products Inc. Durch hydrogel gesteuerte mehrschichtige dosierungsform enthaltend sertralin
EP1554572B1 (de) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US6988556B2 (en) * 2002-02-19 2006-01-24 Halliburton Energy Services, Inc. Deep set safety valve
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
WO2004024130A2 (en) * 2002-09-16 2004-03-25 Sepracor, Inc. TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP1542961B1 (de) * 2002-09-16 2013-09-11 Sepracor, Inc. Trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamin zur behandlung von zns-krankheiten
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BRPI0418244A (pt) * 2003-12-29 2007-04-17 Sepracor Inc composto, métodos para aumentar a concentração de d-serina e/ou diminuir a concentração de produtos tóxicos da oxidação de d-serina pela daao em um mamìfero, para tratar a esquizofrenia, para tratar ou prevenir a perda de memória e/ou cognição associadas com o mal de alzheimer, para tratar a ataxia ou para prevenir a perda da função neuronal caracterìstica de doenças neurodegenerativas, para intensificar a aprendizagem, memória e/ou cognição e para tratar dor neuropática, e, composição farmacêutica
JP2008539047A (ja) 2005-04-28 2008-11-13 プロテウス バイオメディカル インコーポレイテッド ファーマインフォーマティックスシステム
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
CA2636324C (en) 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
EP2382975A3 (de) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenese mittels Angiotensin-Modulation
CA2651862A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2043745A2 (de) * 2006-05-31 2009-04-08 SEPRACOR Inc Behandlung von schmerzerkrankungen mit trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalinamin und seinem formamid
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
KR20090071598A (ko) 2006-09-18 2009-07-01 랩터 파마슈티컬 인코포레이티드 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
AU2008206039A1 (en) * 2007-01-18 2008-07-24 Sepracor Inc. Inhibitors of D-amino acid oxidase
KR101581289B1 (ko) 2007-05-31 2015-12-31 세프라코 아이엔시. 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102458374A (zh) 2009-05-06 2012-05-16 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其使用方法
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
JP2017515858A (ja) * 2014-05-13 2017-06-15 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Ａｄｈｄの治療のためのダソトラリンに関する方法および組成物
CN106660937A (zh) * 2014-05-13 2017-05-10 赛诺维信制药公司 用于治疗adhd的达斯曲林(dasotraline)剂量和方法
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
FR3071726B1 (fr) * 2017-09-29 2020-09-04 Univ Paris Sud Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420472A (en) * 1972-09-27 1976-01-07 Pfizer Aminophenyltetralin compounds
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants

Also Published As

Publication number Publication date
HU221624B1 (hu) 2002-12-28
PH26542A (en) 1992-08-19
DE69030212D1 (de) 1997-04-24
JPH02300121A (ja) 1990-12-12
US5061728A (en) 1991-10-29
NZ232800A (en) 1997-07-27
HU901325D0 (en) 1990-05-28
IE900798L (en) 1990-09-07
CA2011428C (en) 1994-11-08
MY106272A (en) 1995-04-29
AU610036B2 (en) 1991-05-09
JPH07173056A (ja) 1995-07-11
JPH0714870B2 (ja) 1995-02-22
DK0386997T3 (da) 1997-04-14
EP0386997A2 (de) 1990-09-12
DE69030212T2 (de) 1997-06-26
IL93576A (en) 1995-12-08
PT93351B (pt) 1996-03-29
JP3020808B2 (ja) 2000-03-15
US4981870A (en) 1991-01-01
EP0386997A3 (de) 1992-04-29
PT93351A (pt) 1990-11-07
KR920005810B1 (ko) 1992-07-20
IE81047B1 (en) 1999-12-01
KR900013949A (ko) 1990-10-22
AU5079690A (en) 1990-09-20
IL93576A0 (en) 1990-11-29
CA2011428A1 (en) 1990-09-07
EP0386997B1 (de) 1997-03-19
HUT59000A (en) 1992-04-28
ZA901743B (en) 1991-10-30

Similar Documents

Publication Publication Date Title
ATE150299T1 (de) Verwendung von derivaten des 4-phenyl-1,2,3,4- tetrahydro-1-naphthalenamins zur behandlung von psychose, entzündung und als immununterdrücker
ATE243694T1 (de) 4-mercaptoacetylamino-(2)benzazepinon(3)- derivate, und verwendung als enkephalinase- inhibitoren
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
BR9300707A (pt) Composicao para o tratamento dos cabelos e processo de condicionamento dos cabelos
DE69019363D1 (de) Desinfizierende zusammensetzung und desinfektionsverfahren.
DE69212620D1 (de) Verwendung von Glycosaminoglycanen zur Behandlung von diabetischer Nephropathie und diabetischer Neuropathie
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
DE69405919D1 (de) Zusammensetzungen zur Behandlung von Keratinfasern
FR2491334B1 (de)
DE69110713D1 (de) 7-Oxabicycloheptan-imidazol-prostaglandin-Analoge, verwendbar bei der Behandlung von thrombotischen und vasospastischen Erkrankungen.
DE69033413D1 (de) Mittel zur Behandlung von Metalloberflächen
DE69007486D1 (de) Verwendung von calciumantagonisten für die behandlung von narben.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
ATE107165T1 (de) Verwendung von macrolactonen als antiallergica.
DE69006508D1 (de) Azeotropähnliche zusammensetzungen von 1,3-dichlor-1,1,2,2,3-pentafluorpropan und 2-methyl-2-propanol.
IL89901A0 (en) Strobilurine derivatives
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
DE69226171D1 (de) Zusammensetzung und verwendung von substituierten 1,3-dithiolo- und 1,4-dithiino-chinoxalinen als antimikrobielle mittel
DE69117566D1 (de) Verwendung von Isomonoolen zur Behandlung und Prophylaxe von Krebserkrankungen
GR3020597T3 (en) Phospholipids for the treatment of multiple sclerosis
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
ATE72979T1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee